GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Price-to-Funds-From-Operations

Vaxart (STU:NB11) Price-to-Funds-From-Operations : (As of Jun. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Vaxart Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Vaxart (STU:NB11) Business Description

Industry
Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.